Ixico (LON:IXI) announced its quarterly earnings data on Monday, December 11th. The company reported GBX (5.70) (($0.08)) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of GBX (4.90) (($0.07)) by GBX (0.80) (($0.01)), Bloomberg Earnings reports. Ixico had a negative net margin of 33.90% and a negative return on equity of 35.21%. The business had revenue of GBX 411 million during the quarter.
Shares of Ixico (LON:IXI) traded down GBX 0.38 ($0.01) during mid-day trading on Tuesday, reaching GBX 36.12 ($0.48). 16,352 shares of the company’s stock were exchanged, compared to its average volume of 8,117. Ixico has a 1 year low of GBX 22.20 ($0.30) and a 1 year high of GBX 39 ($0.52). The company has a market capitalization of $11.17 and a PE ratio of -602.00.
ILLEGAL ACTIVITY WARNING: “Ixico (IXI) Announces Quarterly Earnings Results” was posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.truebluetribune.com/2018/01/03/ixico-ixi-posts-earnings-results-misses-expectations-by-0-80-eps.html.
Ixico Company Profile
IXICO plc is a brain health company. The Company’s brain health focus includes Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, behavioral health and adolescent mental health. It is a provider of clinical trials services to pharmaceutical companies. Its products include Assessa, mehealth, MyBrainBook and TrialTracker.
Receive News & Ratings for Ixico Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ixico and related companies with MarketBeat.com's FREE daily email newsletter.